Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

AI Briefing

• – Alfasigma reports solid performance in 2025 with double-digit revenue growth in Immunology, Gastroenterology, and Vascular, and expansion in international Consumer Healthcare markets.
• – Company's results reflect strategic evolution despite voluntary withdrawal of Ocaliva from the US market.
• – Alfasigma achieves market share growth through disciplined business strategy.